Biovaxys Technology OTC Stock Top Insiders

BVAXF Stock  USD 0.04  0.0004  1.04%   
Biovaxys Technology employs about 17 people. The company is managed by 3 executives with a total tenure of roughly 40 years, averaging almost 13.0 years of service per executive, having 5.67 employees per reported executive. Examination of Biovaxys Technology's management performance can provide insight into the company performance.
David Berd  Insider
CoFounder Officer
Kenneth Kovan  Insider
Pres CoFounder
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biovaxys Technology Corp. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in interest.

Biovaxys Technology Management Team Effectiveness

The company has return on total asset (ROA) of (0.3779) % which means that it has lost $0.3779 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7323) %, meaning that it generated substantial loss on money invested by shareholders. Biovaxys Technology's management efficiency ratios could be used to measure how well Biovaxys Technology manages its routine affairs as well as how well it operates its assets and liabilities.

Biovaxys Technology Workforce Comparison

Biovaxys Technology Corp is rated fifth in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 473. Biovaxys Technology holds roughly 17.0 in number of employees claiming about 4% of stocks in Biotechnology industry.

Biovaxys Technology Corp Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Biovaxys Technology Corp Price Series Summation is a cross summation of Biovaxys Technology price series and its benchmark/peer.

Biovaxys Technology Notable Stakeholders

A Biovaxys Technology stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biovaxys Technology often face trade-offs trying to please all of them. Biovaxys Technology's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biovaxys Technology's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
David BerdCoFounder OfficerProfile
Kenneth KovanPres CoFounderProfile
James PassinCEO CoFounderProfile

About Biovaxys Technology Management Performance

The success or failure of an entity such as Biovaxys Technology Corp often depends on how effective the management is. Biovaxys Technology management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biovaxys management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biovaxys management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320 and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. BIOVAXYS TECHNOLOGY is traded on OTC Exchange in the United States.
The data published in Biovaxys Technology's official financial statements typically reflect Biovaxys Technology's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Biovaxys Technology's quantitative information. For example, before you start analyzing numbers published by Biovaxys accountants, it's essential to understand Biovaxys Technology's liquidity, profitability, and earnings quality within the context of the Healthcare space in which it operates.

Biovaxys Technology Workforce Analysis

Traditionally, organizations such as Biovaxys Technology use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biovaxys Technology within its industry.

Biovaxys Technology Manpower Efficiency

Return on Biovaxys Technology Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee379.9K
Net Loss Per Executive2.2M
Working Capital Per Employee2.1M
Working Capital Per Executive11.7M

Complementary Tools for Biovaxys OTC Stock analysis

When running Biovaxys Technology's price analysis, check to measure Biovaxys Technology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biovaxys Technology is operating at the current time. Most of Biovaxys Technology's value examination focuses on studying past and present price action to predict the probability of Biovaxys Technology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biovaxys Technology's price. Additionally, you may evaluate how the addition of Biovaxys Technology to your portfolios can decrease your overall portfolio volatility.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Bonds Directory
Find actively traded corporate debentures issued by US companies